Adaptive Biotechnologies Highlights NCCN Guideline Updates Naming clonoSEQ For MRD Assessment In Multiple Myeloma

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced significant updates to the NCCN Clinical Practice Guidelines for Multiple Myeloma, which now include a dedicated framework for routine minimal residual disease (MRD) assessment. The guidelines highlight clonoSEQ as an FDA-cleared assay with a preferred sensitivity of 10-6 for MRD testing. This update emphasizes the importance of MRD testing in myeloma management, potentially improving patient outcomes by facilitating informed discussions between patients and healthcare providers.